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The androgen receptor (AR) activation function 2 re-
gion of the ligand binding domain binds the LXXLL mo-
tifs of p160 coactivators weakly, engaging instead in an
androgen-dependent, interdomain interaction with an
FXXLF motif in the AR NH2 terminus. Here we show that
FXXLF motifs are present in previously reported AR
coactivators ARA70/RFG, ARA55/Hic-5, and ARA54,
which account for their selection in yeast two-hybrid
screens. Mammalian two-hybrid assays, ligand dissocia-
tion rate studies, and glutathione S-transferase adsorp-
tion assays indicate androgen-dependent selective in-
teractions of these FXXLF motifs with the AR ligand
binding domain. Mutagenesis of residues within activa-
tion function 2 indicates distinct but overlapping bind-
ing sites where specificity depends on sequences within
and flanking the FXXLF motif. Mutagenesis of the
FXXLF motifs eliminated interaction with the ligand
binding domain but only modestly reduced AR coactiva-
tion in transcription assays. The studies indicate that
the FXXLF binding motif is specific for the AR and me-
diates interactions both within the AR and with coregu-
latory proteins.
The androgen receptor (AR)1 belongs to the steroid receptor
subfamily of hormone-dependent nuclear receptor transcrip-
tional regulators. Recent studies have established general
mechanisms of steroid hormone receptor transcriptional acti-
vation. Binding of cognate ligands induces a conformational
change in the ligand binding domain which results in formation
of a novel hydrophobic interaction surface referred to as acti-
vation function 2 (AF2). AF2 recruits LXXLL motif-containing
p160 coactivator complexes that have histone acetyltransferase
activity (1), resulting in modification of local chromatin struc-
ture to facilitate transcription initiation (2). It is believed that
interaction between the p160 coactivator LXXLL motifs and
the AF2 surface in the ligand binding domain is required for
transactivation of nuclear receptors (3–6). We (7) and others
(8–14) have reported that the AR and other nuclear receptors
also interact with p160 coactivators through their NH2-termi-
nal regions.
The ligand binding domain of some nuclear receptors is also
involved in a ligand-dependent, NH2-terminal/carboxyl-termi-
nal (N/C) interaction, shown for the AR (15), estrogen receptor
 (ER) (16), and progesterone receptor (17). For AR, the an-
drogen-induced N/C interaction slows the androgen dissocia-
tion rate (7, 18–20), prolongs the AR half-life in the presence of
androgen (19, 21), and reduces AF2-mediated transcriptional
activity (19). The AR N/C interaction is direct and involves
interactions between FXXLF and WXXLF motifs in the NH2-
terminal domain with the AF2 binding surface in the ligand
binding domain (7, 18, 19). In contrast, the ER N/C interac-
tion may be indirect, mediated by TIF2 or p300/CBP (22, 23).
The crystal structure of the AR ligand binding domain reveals
an overall structural arrangement similar to other steroid re-
ceptors (24, 25) with subtle changes that seem to favor the N/C
interaction. Under normal physiological conditions, AF2 bind-
ing of the NH2-terminal FXXLF motif is favored over binding
the LXXLL motifs of p160 coactivators, which likely contrib-
utes to the weak AR AF2 transcriptional activity in mamma-
lian cells (7, 18, 19). The AR AF2 region nevertheless interacts
with the LXXLL motifs of p160 coactivators when these coac-
tivators are overexpressed (7). We recently proposed such a
mechanism to account for the recurrent growth of prostate
cancer under conditions of androgen deprivation (26). In the
present report we investigated the role of the FXXLF motif in
androgen-dependent AR interactions with previously reported
AR coactivators.
EXPERIMENTAL PROCEDURES
Plasmid Constructions—Coding sequences for FXXLF and LXXLL
motif-containing peptides were cloned in pGAL0 (15), which expresses
the Saccharomyces cerevisiae GAL4 DNA binding domain amino acid
residues 1–147 expressed NH2-terminal to the peptide sequences.
GAL4 peptide fusion plasmids were created using two complementary
oligonucleotides that were phosphorylated by T4 polynucleotide kinase,
denatured, annealed at room temperature, and cloned at NdeI/XbaI in
pGAL0. Oligonucleotides coding for the FXXLF or LXXLL motifs typi-
cally contained coding sequence for 7 additional flanking amino acids,
with peptides ranging in size from 11 to 21 amino acids.
AR-FXXAA (pCMVhAR-L26A/F27A) had 23FQNLF27 changed to
23FQNAA27, and AR-FXXAA/WXXAA (pCMVhAR-L26A/F27A/L436A/
F437A) had the additional mutation of 433WHTLF437 changed to
433WHTAA437 (18, 19). VPAR507–919, pVP16-ER-LBD (ER amino
acid residues 312–595), VP16-PR-A, and the 5XGAL4Luc3 reporter
were gifts from Donald P. McDonnell, Duke University. VPAR-(507–
919) (AR DNA and ligand binding domains) and pVP16-ER-LBD con-
tained the herpes simplex virus VP16 transactivation domain residues
411–456. pCMVhAR-K720A, pCMVhAR-E897K, and pCMVhAR-
V716R are full-length AR expression vectors with single mutations in
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AF2 of the ligand binding domain (7). pCMVhAR-(507–919) codes for
the human AR DNA and ligand binding domains (27). pCMVhAR142–
337 and pCMVhAR142–337L26A/F27A (AR142–337FXXAA) have
the AF1 region deleted in the NH2-terminal domain (19, 28).
Glutathione S-transferase (GST)-ARA54-(432–474), GST-ARA70-
(320–407), GST-ARA55-(405–444), and GST-ARA55-(301–340) were
constructed by amplifying the indicated DNA regions using PCR, and
the inserts were cloned into pGEX-3X (Amersham Biosciences, Inc.) at
EcoRI/BamHI. pcDNA3HA-AR-LBD for in vitro translation expressing
human AR ligand binding domain residues 624–919 was created by
digesting GAL-AR-(624–919) with BamHI/XbaI and the insert cloned
at the same sites in pcDNA3HA.
pSG5-HAmHic5 (pSG5-HA-ARA55) was a gift from Michael R. Sta-
llcup, University of Southern California, Los Angeles. pCMV-sport6-A-
RA54 (clone CS0DI083YK17) and FHL2 (clone CS0DK007YN06) (Invi-
trogen) had coding inserts cloned at SalI/NotI. pSG5-HA-ARA54 was
constructed by amplifying the coding region of ARA54 from pCMV-
sport6-ARA54 using PCR, with the 1.4-kb insert cloned in pSG5-HA at
EcoRI/XhoI. The 5-primer had an EcoRI site, and the 3-primer had an
XhoI site. DNA amplification using PCR was used to create pSG5-HA-
ARA54-L457A/F458A with the insert cloned at HindIII/BamHI and
pSG5-HA-ARA55-L442A/F443A with the insert cloned at BstEII/XhoI.
The mutagenesis strategy was a two-step PCR to create pSG5-HA-
ARA55-L325A/F326A with the insert cloned at BstEII/XhoI. pSG5-HA-
ARA55-L325A/F326A/L442A/F443A was created by amplifying pSG5-
HA-ARA55-L325A/F326A with the insert cloned in pSG5-HA-ARA55-
L442A/F443A at BstEII/XhoI. ARA70-(320 – 407)-AR-(172–919)-
AXXAA (where AXXAA is human AR mutation W433A/L436A/F437A),
ARA54-(398 – 474)-AR-(172–919)-AXXAA, ARA55-(281–361)-AR-
(172–919)-AXXAA, ARA55-(269 – 444)-AR-(172–919)-AXXAA, and
ARA55-(281–444)-AR-(172–919)-AXXAA were constructed by DNA
amplification using PCR of the indicated regions and cloning the inserts
at BglII/AflII of AR-W433A/L436A/F437A (19). Constitutively active
luciferase reporter vectors included pSG5-Luc (from Kurt Hoffman and
Walter Heyns, Catholic University of Leuven, Belgium), pSV2-Luc
(from P. Kay Lund, University of North Carolina at Chapel Hill), and
pA3RSV400Luc (from Arthur Gutierrez-Hartman, University of Colora-
do, Denver). In D11-FXXLF-AR, a D11 peptide sequence (29) was mod-
ified to replace the LXXLL motif with FXXLF (see Fig. 1) and con-
structed to replace AR amino acid residues 16–34 by DNA amplification
of pCMVhAR using a 5-BglII-D11 oligonucleotide and a 3-oligonu-
cleotide at the AR AflII site. The fragment was inserted into pCMVhAR
digested with BglII/AflII and reamplified using a 5-oligonucleotide
containing a BglII site and coding sequence for AR NH2-terminal 1–15
amino acids and part of the D11 peptide coding sequence and the
3-AflII oligonucleotide. The resulting fragment was reinserted into the
BglII/AflII site of pCMVhAR. GAL-ARA70-(321–499), GAL-ARA70-
(321– 499)-F328A/L331A/F332A (GAL-ARA70-(321– 499)-AXXAA),
GAL-ARA54-(361– 474), and GAL-ARA54-(361– 474)-L457A/F458A
(GAL-ARA54-(361–474)-FXXAA) were constructed by DNA amplifica-
tion of the indicated regions using PCR and the inserts cloned into
GAL0 at NdeI/SacI. GAL-ARA55-(251– 444) and GAL-ARA55-
(251– 444)-L325A/F326A/L442A/F443A (GAL-ARA55-(251– 444)
(FXXAA)2) were constructed by amplifying the indicated regions using
PCR, and the inserts were cloned into GAL0 at NdeI/XbaI. Amplifica-
tion of plasmid DNA by PCR was done using Vent-polymerase, and all
amplified regions were verified by DNA sequencing.
Mammalian Two-hybrid Assays—Human hepatocellular carcinoma
HepG2 cells (American Type Culture Collection) were maintained in 5%
CO2 at 37 °C in Eagle’s minimum essential medium (Invitrogen) con-
taining 10% fetal bovine serum (Hyclone), 0.1 mM nonessential amino
acids, 1 mM sodium pyruvate, 2 mM L-glutamine, and penicillin/strep-
tomycin. For peptide interaction assays, HepG2 cells were plated at 2 
105 cells/well of 12-multiwell tissue culture plates. The next day me-
dium was exchanged with 0.8 ml of fresh culture medium. DNA for
transfection was prepared for 4 wells each following the Effectene
protocol (Qiagen). Wild-type or mutant pCMVhAR, pCMVhGR,
VP16PRA, or VP16-ER-LBD (0.05 g) or VPAR507–919 (0.15 g) was
combined with 0.05 g of GAL4-peptide DNA/well and 0.1 g of
5XGAL4Luc3/well in 75 l of EC buffer/well, 1 l of enhancer/well, 1 l
of Effectene/well, and 0.4 ml of media/well, and 400 l was added to the
plates. The next day cells were washed in phosphate-buffered saline
and the media replaced with serum-free medium lacking phenol red.
Hormones were added as indicated, and cells were incubated overnight
at 37 °C. The next day cells were washed with phosphate-buffered
saline and harvested in 220 l of lysis buffer (25 mM Tris phosphate, pH
7.8, 2 mM EDTA, 1% Triton X-100), and 0.1 ml was analyzed using a
Monolight 2010 (Analytical Luminescence Laboratories) or LumiStar
Galaxy (BMG Labtechnologies) luminometer.
Human epithelioid cervical carcinoma HeLa cells were maintained in
Eagle’s minimum essential medium supplemented with 10% fetal bo-
vine serum and 2 mM L-glutamine and penicillin/streptomycin. HeLa
cells (3.5  105 cells/6-cm dish) were transfected using Effectene as
described above except using 0.25 g each of VPAR507–919, GAL4-
peptide, and 5XGAL4Luc3, 150 l of EC buffer/plate, and 4 l each of
enhancer and Effectene/plate in 1 ml of media were added to plates
containing 3 ml of fresh media. After 24 h cells were washed in phos-
phate-buffered saline, and 4 ml of serum-free medium lacking phenol
red was added per plate. Cells were incubated for 24 h in the absence or
presence of the indicated hormones and assayed for luciferase activity
as described above except using 0.5 ml of lysis buffer/plate.
In Vitro Binding Assays—GST fusion proteins were expressed in
XL1-Blue Escherichia coli cells treated with 0.5 mM isopropyl -D-
thiogalactopyranoside for 3 h after log phase growth. Bacteria were
sonicated in 0.5% Nonidet P-40, 1 mM EDTA, 0.1 M NaCl, 0.02 M
Tris-HCl, pH 8.0, centrifuged, and the supernatant was incubated with
glutathione-agarose beads (Amersham Biosciences, Inc.) for 1 h at 4 °C
(7). Beads were washed five times with the sonication buffer and incu-
bated for 2 h at 4 °C with and without 1 M dihydrotestosterone (DHT).
In vitro translated proteins were labeled with 25 Ci of [35S]methionine
(PerkinElmer Life Sciences) using the TNT T7 Quick Coupled Tran-
scription/Translation System (Promega) in the presence and absence of
1 M DHT. Beads were centrifuged, washed five times, and boiled in
SDS. Input lanes contained 10% of that used for the binding reactions.
Transcription Assays—Transient transcriptional activity of wild-
type and mutant AR was determined in the presence and absence of
cotransfecting expression vectors for the putative AR coactivators. Mon-
key kidney CV1 cells were transiently transfected using calcium phos-
phate precipitation (19). Wild-type and mutant pCMVhAR DNA (100
ng/6-cm dish) were precipitated with 5 g of mouse mammary tumor
virus luciferase reporter vector DNA. Cells were incubated for 48 h in
the absence and presence of the indicated hormones, harvested, and
assayed for luciferase activity as described above.
Ligand Dissociation Assays—Dissociation half-times of [3H]R1881
(methyltrienolone, 70–87 Ci/mmol, PerkinElmer Life Sciences) from
AR were determined at 37 °C in monkey kidney COS-1 cells using 4 
105 cells/well in 6-well plates transfected with 2 g of wild-type or
mutant pCMVhAR DNA/well using DEAE-dextran (19). Cells were
incubated for 2 h at 37 °C with 5 nM [3H]R1881 in the presence and
absence of a 100-fold excess unlabeled R1881. Radiolabeled ligand
dissociation was started by the addition of 50 M unlabeled R1881 and
the cells incubated for increasing times at 37 °C up to 3 h, washed once,
and harvested in 0.5 ml of 10 mM Tris, pH 6.8, 2% SDS, and 10%
glycerol, with radioactivity determined by scintillation counting. In
previous studies we reported overall slower ligand dissociation half-
times for AR (18–21) caused by the actual temperature of the incubator
being 35 °C rather than the 37 °C incubation during the dissociation
phase of the experiments.
Immunoblot Analysis—Relative expression levels of the GAL4-pep-
tide fusion proteins were determined by immunoblot analysis. COS-1
cells (1.2  106 cells/10-cm dish) were transfected using the Effectene
kit protocol. On the 2nd day, 8 ml of medium was added to each plate,
and the DNA was suspended in 0.3 ml of EC buffer (Qiagen). The DNA
for each plate was combined with 16 l of enhancer and 10 l of
Effectene reagent and added to the cells in 1 ml of medium. Peptide
detection by immunoblot was increased by the addition of 1 M MG132
(Sigma), a proteosome inhibitor, 24 h prior to cell harvest. Addition of
MG132 did not significantly alter the interaction assay results. Nuclear
extracts of transfected COS cells were prepared as described previously
(30). Protein concentrations were determined using the Bio-Rad protein
assay with bovine serum albumin as standard. Proteins (10 g) were
separated on 12% acrylamide gels containing SDS, and the GAL4-
peptide fusion proteins were detected using the anti-GAL4-DNA bind-
ing domain monoclonal antibody (Santa Cruz Biotechnology, Inc.).
RESULTS
FXXLF Interacting Motifs in AR Coactivators—Previous
studies in our laboratory showed that the AF2 region of the AR
ligand binding domain binds preferentially in the presence of
androgen an AR NH2-terminal FXXLF motif (
23FQNLF27) com-
pared with the LXXLL motifs of the p160 coactivators (18, 19).
We have now investigated whether a group of reported AR
coactivators contain FXXLF motifs, which might account for
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their selection in two-hybrid screens where the AR ligand bind-
ing domain was used as probe. A search of the sequences
revealed that ARA70 (31, 32), ARA55 (33, 34), and ARA54 (35)
each contain one (ARA70 and ARA54) or two (ARA55) FXXLF
motifs. In each case the FXXLF sequences are in regions se-
lected previously by yeast two-hybrid screens. Regions of the
recruited fragments (underlined) and the position and se-
quence of the FXXLF motif regions are shown in Fig. 1.
Interaction of the AR coactivator FXXLF motifs with the AR
ligand binding domain was tested in the absence and presence
of 10 nM DHT using two-hybrid peptide assays (29) in HeLa or
HepG2 cells with GAL4-peptide fusions. Expression of the
GAL4-peptide fusions was verified on immunoblots of nuclear
extracts from cells treated for 24 h with MG132, a proteosome
inhibitor (Fig. 2A). Results are shown for COS cell expression,
but similar results were obtained using HeLa cells. Peptide
detection in both cases required the addition of MG132, but
treatment with MG132 did not alter the interaction results
(data not shown). Androgen-dependent interactions were de-
tected which increased luciferase activity by 8–48-fold in two-
hybrid assays between VPAR507–919 (AR DNA and ligand
binding domain) and the GAL4-FXXLF fusion peptides with
sequences from AR (GAL-AR-(16–36)), ARA54 (GAL-ARA54-
(447–465)), and ARA70 (GAL-ARA70-(321–340)) (Fig. 2B). Mu-
tation of FXXLF to FXXAA in GAL-AR-(16–36) eliminated the
interaction based on loss of luciferase activity in the two-hybrid
assay (Fig. 2B). The results indicate a requirement for the
FXXLF binding motif in the AR-interacting peptide. Decreas-
ing the size of the AR FXXLF peptide sequence from residues
16–36 to 20–30 increased the magnitude of the interaction of
the GAL4-AR-FXXLF peptide, with luciferase activity increas-
ing from 8- to 31-fold in the two-hybrid assay (Fig. 2B). This
result provided the first indication that amino acid residues
flanking the AR FXXLF sequence influence the interaction
FIG. 2. Immunoblot and GAL-FXXLF fusion peptide interac-
tions. Panel A, GAL-FXXLF peptides were expressed in COS cells in
the presence of 1 M MG132 using Effectene reagent as described under
“Experimental Procedures.” Nuclear extracts (10 g of protein) were
analyzed, and blots were exposed to GAL4 DNA binding domain anti-
body. Shown are the banding patterns after expressing the empty
vector GAL0 and the GAL-peptide fusions indicated. Panel B, GAL-
peptide fusions (0.25 g of DNA) were expressed in HeLa cells with 0.25
g of VPAR507–919 (AR DNA and ligand binding domain) and 0.25 g
of 5XGAL4Luc3 reporter vector using Effectene as described under
“Experimental Procedures.” Cells were incubated for 24 h in the ab-
sence and presence of 10 nM DHT. Shown is a representative experi-
ment of at least three independent determinations for GAL0 empty
vector and GAL-AR-(16–36), GAL-AR-(16–36)-FXXAA (AR16–36AA),
GAL-AR-(20–30) (AR20–30), GAL-ARA54-(447–465) (ARA54), GAL-
ARA70-(321–340) (ARA70), GAL-D11-FXXLF (D11Fx), GAL-ARA55-
(314–332) (ARA55–1), GAL-ARA55-(427–444) (ARA55–2), GAL-TIF2-
(683–701) (TIF2–2), and GAL-TIF2-(738–756) (TIF2–3). Fold induction
relative to the luciferase activity determined in the absence of DHT is
shown above the bars. Panel C, GAL-peptide DNA (0.05 g) was ex-
pressed in HepG2 cells in the absence and presence of 10 nM DHT with
0.05 g of pCMVhAR and 0.1 g of 5XGAL4Luc3 reporter as described
under “Experimental Procedures.” The abbreviations are the same as
described above. Fold induction relative to activity determined in the
absence of DHT is shown above the bars. The data are representative of
at least three independent experiments.
FIG. 1. Schematic diagram of AR and reported AR coregula-
tory proteins and amino acid sequence of the FXXLF motif
regions. Shown schematically are full-length AR (amino acid residues
1–919) and previously reported AR coactivators ARA70-(1–614),
ARA54-(1–474), and ARA55-(1–444). Shown in the AR diagram is the
DNA binding domain (DBD) and ligand binding domain (LBD). The
dotted underlined regions highlight fragment regions cloned previously
in yeast two-hybrid screens using the AR ligand binding domain as
probe (31–35). The dark rectangles indicate the positions of the FXXLF
motif sequences. Below are shown amino acid sequences of the FXXLF
motif regions for AR and the coregulators. The GAL4-DNA binding
domain fusion peptides contained the sequences shown. The AR peptide
sequences tested in the two-hybrid assays were AR16–36 with QN at
the carboxyl terminus or only residues 20–30. The carboxyl-terminal
FXXLF peptide GAL-ARA55-(427–444) included QERAS at the NH2-
terminal end. GAL-ARA70-(321–340) had a carboxyl-terminal Trp res-
idue. The last Ser in QERAS is Gly in the human sequence.
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with AF2. No interaction was observed in the two-hybrid pep-
tide assay using either of the two GAL-ARA55-FXXLF pep-
tides, providing further evidence that sequences within and
flanking the FXXLF motif influence the extent of binding.
Similarly, no luciferase activity resulted from any of the GAL-
peptides alone because there was no transcriptional activity
detected in the absence of androgen (see Figs. 2, B and C, and
3). In a positive control, we observed an 84-fold DHT-dependent
interaction with a GAL-D11-FXXLF peptide (D11FX). The D11
peptide contains an LXXLL motif that interacts with AR (29),
which we changed to conform to an FXXLF motif as described
previously (36). Interaction was also detected between
VPAR507–919 and the third LXXLL motif sequence of TIF2
but not with the second LXXLL motif (Fig. 2B).
To investigate further the interactions of the FXXLF motif
sequences, the two-hybrid assay was performed in HepG2 cells
using full-length AR instead of the DNA and ligand binding
domain fragment. Each of the GAL4-FXXLF peptides with
sequence derived from AR, ARA70, ARA54, and the D11-
FXXLF peptide interacted with the AR, with an increase in
luciferase activity of 35–228-fold (Fig. 2C). No interaction or
background activity was observed using AR and the empty
GAL0 vector control or when the GAL-AR-(16–36)-FXXLF se-
quence was mutated to FXXAA (Fig. 2C). In this assay there
were weaker interactions detected with the GAL-ARA55 fusion
peptides containing the first or second FXXLF sequence. The
third LXXLL motif of TIF2 in residues 738–756 increased
luciferase activity in the two-hybrid assay by 3-fold, whereas
again, no interaction was detected with the second LXXLL
motif of TIF2 between residues 683 and 701 (Fig. 2C). The
reporter vector used in these assays has five GAL4 binding
sites in the promoter region. Although two-hybrid assays pro-
vide an indirect measurement of protein interactions, previous
GST adsorption studies using mutants of the AF2 region in the
AR ligand binding domain indicated a direct interaction with
the FXXLF motif (19). The increase in luciferase activity thus
depended on the recruitment of full-length AR by the GAL4-
peptide fusions. The results raised the possibility that FXXLF
sequences in ARA54 and ARA70, but probably not ARA55 or
the LXXLL motifs of TIF2, interact sufficiently to compete for
the androgen-dependent and specific N/C interaction (7, 15,
18–21). Alternatively, interactions may occur with the andro-
gen-bound AR monomer, which may or may not undergo an
intramolecular N/C interaction (20).
To demonstrate that the FXXLF motif sequences in the AR-
interacting proteins accounted for their selection in previous
yeast two-hybrid screens using the AR ligand binding domain
as probe (31–35), the fragments shown underlined in Fig. 1
were expressed as fusion proteins with the GAL4 DNA binding
domain in HeLa cells with full-length AR. Mutagenesis of the
FXXLF motifs in the GAL fusion proteins of ARA54-(361–474),
ARA70-(321–499), and ARA55-(251–444) reduced the overall
luciferase activity to the level seen with empty vector GAL0
(Fig. 3). There was high background transcriptional activity
induced by full-length AR in the HeLa cell two-hybrid protein
interaction assay using the 5XGAL4Luc reporter (Fig. 3) which
was not detected in HepG2 cells (see Fig. 2C). This resulted
from a cryptic androgen response element because similar
background activity was observed in HeLa cells using the par-
ent reporter vector pGL3-basic luciferase (data not shown).
In Vitro Interactions—GST adsorption assays were per-
formed to investigate further the androgen-dependent interac-
tions between the FXXLF motif-containing fragments and the
AR ligand binding domain. With each of the GST-FXXLF se-
quences derived from ARA55, ARA54, and ARA70, interaction
with 35S-labeled AR624–919 containing the AR ligand binding
domain increased in the presence of androgen (Fig. 4, lanes
3–10). The FXXLF sequence was required for the interaction
because mutation to AXXAA eliminated interaction, as shown
for ARA70 (Fig. 4, lanes 9–12). Similar results in mammalian
two-hybrid assays indicated the requirement for the FXXLF
motif in the AR NH2-terminal motif interaction (see Fig. 2, B
and C). On the other hand, the FXXLF motif sequence FGSLF
in the transcriptional regulators p300-(26–44) (37) and CBP-
(23–41) (38), and FETLF in FHL2-(25–43) (39), failed to inter-
act in mammalian two-hybrid and GST adsorption assays us-
ing the AR ligand binding domain or full-length AR (data not
shown). The results provide further evidence that sequences
within and flanking the FXXLF motifs influence the androgen-
dependent interaction with the AR ligand binding domain. In
support of this, mutation of the flanking sequence of the ARA70
FXXLF motif from KFKLLF to AFALLF abolished binding to
the AR ligand binding domain (32). The LXXLL motif region of
TIF2 also interacts with the AR ligand binding domain in GST
adsorption assays (7). Two-hybrid results suggest that this is
primarily the result of the third LXXLL motif of TIF2 (see Fig.
2, B and C).
Effects of Coactivator FXXLF Sequences on Androgen Disso-
ciation Rate—Previously we showed that the AR N/C interac-
tion slows the dissociation kinetics of bound [3H]R1881, a ra-
FIG. 3. Interaction of coactivator fragments with AR. HeLa cells
were transfected using Effectene as described under “Experimental
Procedures” with 0.15 g of pCMVhAR, 0.25 g of 5XGAL4Luc3
reporter vector either with no further addition () or with 0.15 g of
GAL0 empty vector or GAL-AR-(16–36), GAL-ARA54-(361–474), GAL-
ARA54-(361– 474)-L457A/F458A(FXXAA), GAL-ARA70-(321– 499),
GAL-ARA70-(321–499)-F328A/L331A/F332A (AXXAA), GAL-ARA55-
(251– 444), or GAL-ARA55-(251– 444-L325A/F326A/L442A/F443A)
(FXXAA2). Cells were incubated in the absence and presence of 10 nM
DHT. Data shown are representative of three independent
experiments.
FIG. 4. GST-peptide adsorption assays with 35S-labeled AR li-
gand binding domain. The GST-0 empty parent vector pGEX-3X or
the GST fusion peptides indicated were expressed in E. coli as described
under “Experimental Procedures” in the absence and presence of 1 M
DHT and 35S-labeled AR-(624–919) expressing ligand binding domain
residues 624–919. The input lane represents 10% of the total 35S-
labeled AR-(624–919) used in each sample.
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diolabeled synthetic androgen, and that this effect is dependent
on the NH2-terminal FXXLF motif (18, 20, 21). The dissociation
half-time of [3H]R1881 of 111  10 min for wild-type AR de-
termined at 37 °C increased to 45 and 32 min, respectively,
when the AR NH2-terminal FXXLF motif, or both the FXXLF
and WXXLF motifs, were mutated (Fig. 5) as reported previ-
ously (18, 19). We created coactivator-AR chimeras in which
the AR FXXLF motif region was deleted, and the AR WXXLF
motif was mutated to eliminate the inherent AR N/C interac-
tion (see Fig. 5). The effectiveness of this assay in demonstrat-
ing domain interactions was shown previously using p160 co-
activator-glucocorticoid receptor chimeras containing the
LXXLL motif region of TIF2, where the ligand dissociation
half-time increased 5–6-fold (19).
When the 171 AR NH2-terminal amino acid region was re-
placed by ARA54 residues 398–474 containing its FXXLF mo-
tif (chimera ARA54-(398–474)AR-(172–919)-AXXAA), the half-
time of [3H]R1881 dissociation was 84  7 min compared with
111  10 min for wild-type AR and 45  1 and 32  3 min for
AR-FXXAA and AR-FXXAA/AXXAA, respectively (Fig. 5). This
dissociation half-time provides evidence in support of the an
interaction between the ARA54 FXXLF sequence and the AR
ligand binding domain. In contrast, chimeras containing the
FXXLF regions from ARA70 (ARA70-(320–407)-AR-(172–919)-
AXXAA; t1/2 39  1), ARA55 (ARA55-(281–361)-AR-(172–919)-
AXXAA and ARA55-(369–444)-AR-(172–919)-AXXAA; t1/2 37–
38  3–5 min), or a construct containing both FXXLF motifs of
ARA55 (ARA55-(281–444)-AR-(172–919)-AXXAA, t1/2 35  1
min), were less effective in slowing the androgen dissociation
half-time (Fig. 5). Indeed, the multiple LXXLL motif region of
TIF2 (TIF2-(627–780)-AR-(172–919)-AXXAA; t1/2 53  2 min)
was more effective in slowing the androgen dissociation half-
time than were the FXXLF regions of ARA70 or ARA55, but
less effective than the FXXLF motif-containing region of
ARA54. Inserting the D11-FXXLF peptide sequence at the
position of the AR NH2-terminal FXXLF motif resulted in an
androgen dissociation half-time of 120  17 min, which is
indistinguishable from that of wild-type AR (Fig. 5). The re-
sults are consistent with the two-hybrid assay results above for
the ARA54-FXXLF sequence and indicate weaker interactions
with the corresponding regions of ARA70 and ARA55.
Sequence Requirements of the AR AF2 Binding Site—We
tested whether certain amino acid residues in the AR AF2
region of the ligand binding domain were required for interac-
tion with the FXXLF motifs of ARA54, ARA55, and ARA70. The
residues tested included lysine 720, whose mutation disrupts
AF2 interaction with TIF2, and glutamic acid 897 and valine
716, mutation of which disrupts, in addition, the AR N/C in-
teraction (7). None of these AR AF2 mutations alters the ap-
parent equilibrium binding affinity for [3H]R1881 (7). Wild-
type and mutant AR expression vectors were cotransfected
with the GAL4-FXXLF and -LXXLL peptides in mammalian
peptide two-hybrid interaction assays. There was a striking
loss of interaction of the ARA54-FXXLF peptide with
AR-K720A. In contrast, interaction of K720A remained robust
with the AR NH2-terminal FXXLF sequence and with the
FXXLF peptides from ARA70 and D11 (Fig. 6A). No interaction
was observed between the AR NH2-terminal FXXLF motif and
AR-E897K as reported previously (7) and comparatively
weaker interactions with FXXLF peptides from ARA54,
ARA70, and D11-FXXLF (Fig. 6A). AR-V716R abolished all
FXXLF peptide interactions. Thus, glutamic acid 897 and va-
line 716 are critical in the AF2 binding surface for interaction
with a variety of FXXLF motif sequences. The requirement for
lysine 720 for the FXXLF sequence from ARA54 and the
LXXLL sequence of TIF2, but not the FXXLF sequences of AR
or ARA55 or ARA70, suggests subtle differences in the AF2
binding surface for FXXLF and LXXLL motif binding.
Receptor Specificity for FXXLF Motif Binding—We next de-
termined whether the AR ligand binding domain selectively
binds the FXXLF motif compared with other steroid receptors.
None of the FXXLF peptide sequences derived from AR,
ARA54, or ARA70 interacted to a significant extent with the
glucocorticoid receptor, the A form of the progesterone receptor
(VP16-PR-A), or with the ER ligand binding domain (VP-ER-
LBD) (Fig. 6B). In striking contrast, the third LXXLL motif of
TIF2 between residues 738 and 756 interacted strongly with
the glucocorticoid and progesterone receptors, with luciferase
activity increasing 92- and 277-fold, respectively, with essen-
tially no interaction detected with the second LXXLL motif of
TIF2 (Fig. 6B). For ER, it was the second LXXLL motif of
TIF2 positioned between TIF2 residues 683 and 701 which
interacted strongly with the ER ligand binding domain, in-
creasing luciferase activity 388-fold. A much weaker interac-
tion was detected between the ER ligand binding domain and
the third LXXLL motif of TIF2 (36-fold, Fig. 6B), in agreement
with previous reports (13, 41). As evident in Fig. 6B, little or no
background transcriptional activity was detected in HepG2
cells for the AR, glucocorticoid receptor, and ER in interaction
assays using the 5XGAL4Luc reporter vector and the empty
GAL-DNA binding domain vector, GAL0. In contrast, 30–50-
fold background transcriptional activity was apparent for
VP16PR-A cotransfected with the GAL0 empty vector or the
GAL-peptides (Fig. 6B). The results demonstrate a high degree
FIG. 5. Ligand dissociation half-
times for AR and chimeras. Shown
schematically are the AR, AR N/C inter-
action mutants AR-FXXAA, and AR-
FXXAA/AXXAA described previously (19)
and AR chimeras containing the indicated
regions of the putative coactivators ex-
pressed as fusion proteins. Construction
of the mutant expression vectors and dis-
sociation half-times were determined as
described under “Experimental Proce-
dures” using [3H]R1881. Shown are the
dissociation half-times in min determined
at 37 °C  S.E. of three independent ex-
periments each determined in duplicate.
The positions of the DNA binding domain
(DBD) and ligand binding domain (LBD)
are indicated.
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of selectivity among a group of related FXXLF and LXXLL
sequences for steroid receptor binding. The AF2 region of the
AR ligand binding domain preferentially binds the FXXLF
motif, whereas other steroid receptors interact more strongly
with the LXXLL motifs.
Role of the FXXLF Motifs in Coactivation of AR-mediated
Gene Transcription—Recruitment and transcriptional activa-
tion by nuclear receptors and p160 coactivators depend on
interactions between AF2 in the ligand binding domain and
LXXLL motifs of p160 coactivators (3–6). Using the mouse
mammary tumor virus luciferase reporter vector, we investi-
gated the requirement for the FXXLF motifs in coactivator
stimulation of AR transcriptional activation. There were only
modest increases in AR-mediated transcriptional activity with
the coexpression of ARA54, ARA55, or ARA70 when the tran-
scriptional response was compared with controls that lacked
the addition of empty vector DNA (Fig. 7A). When equivalent
amounts of empty expression vector (pSG5) were added with
the AR expression vector and mouse mammary tumor virus
luciferase to balance the DNA of the coactivators, there was
inhibition of the transcriptional response compared with that
determined in the absence of control DNA (Fig. 7A). Transcrip-
tional inhibition caused by empty vector DNA therefore re-
sulted in a greater apparent stimulation of AR-mediated tran-
scriptional activity than was observed when empty vector DNA
was omitted in the negative control. Mutating FXXLF to
FXXAA in ARA54 and ARA55 had relatively little effect on the
transcriptional response (Fig. 7A). The use of two expression
vectors for ARA54 (pSG5 for HA-ARA54 and pCMV for ARA54)
demonstrated a different overall response, but in each case
there was no decrease in luciferase activity detected by intro-
ducing a mutation in the FXXLF motif sequence (Fig. 7A). The
results suggest that a direct influence of these AR coregulatory
proteins on the transcriptional response does not depend on
interaction through the FXXLF binding motifs.
We investigated whether the observed decrease in transcrip-
tional response caused by the addition of empty vector DNA
was nonspecific. Empty vector and coregulator plasmids were
expressed in the presence of the constitutively active luciferase
reporters pSV2-Luc, pA3RSV400Luc, and pSG5-Luc. We ob-
served inhibition of transcription with the addition of pSG5
empty vector DNA (Fig. 7B) for each constitutively active re-
porter to an extent similar to the inhibition of AR-mediated
activity seen in Fig. 7A. Inhibition was also observed with
ARA55, but expression of ARA54, ARA70, or TIF2 had little
influence on transcriptional activation. Based on these results,
FIG. 6. AF2 amino acid sequence re-
quirements and steroid receptor
specificity of FXXLF motif interac-
tions. Panel A, GAL-peptide DNA (0.05
g) was cotransfected with pCMVhAR ex-
pressing full-length wild-type (AR) or
with mutant sequences K720A, E897K,
and V716R (0.05 g) and 0.1 g of
5XGAL4Luc3 in HepG2 cells as described
under “Experimental Procedures.” Cells
were incubated in the absence and pres-
ence of 10 nM DHT. The GAL-peptides




GAL-D11-FXXLF (D11Fx). Shown is a
representative experiment of at least
three determinations with the fold induc-
tion relative to activity determined in the
absence of DHT shown above the bars.
Panel B, steroid receptor specificity of
FXXLF sequence interactions was deter-
mined in HepG2 cells using the GAL-pep-
tides (0.05 g) and pCMVhAR (AR),
pCMVhGR (GR), VP-PR-A coding for the
VP16 transactivation domain and PR-A
lacking 164 amino acid residues of full-
length PR-B, and VP-ER-LBD coding for
the VP16 transactivation domain and
ER ligand binding domain residues 312–
595 (0.05 g) with 0.1 g of 5XGAL4Luc3
as described under “Experimental Proce-
dures.” Cells were incubated at hormone
concentrations determined to be optimal:
10 nM DHT for AR, 10 nM dexamethasone
for GR, 10 nM R5020 for PR, and 1 M
estradiol for ER. Abbreviations are as
indicated in panel A. In addition, results
are shown for the GAL-TIF2 peptides con-
taining the second (GAL-TIF2-(683–701)
(TIF-2)) and third (GAL-TIF2-(738–756)
(TIF-3)) LXXLL motif sequences of TIF2.
Data shown are representative of three
independent experiments, and fold induc-
tion is indicated above the bars.
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FIG. 7. Effect of interacting pro-
teins on AR transcriptional activity.
Panel A, AR transactivation was deter-
mined in CV1 cells by transfecting 0.1 g
of pCMVhAR without or with 1 g of
pSG5 parent vector DNA or 1 g of pSG5-
expressed coactivators HA-ARA54 (with





FXXAA) (ARA55(AA)2), TIF2, TIF2-
(LXXAA)3 (TIF2(AA)3, and ARA70 as
described under “Experimental Proce-
dures.” Cells were incubated for 48 h in
the absence and presence of 0.1 nM DHT.
Panel B, constitutive transactivation of
pSV2-Luc, pA3RSV400Luc, and pSG5-Luc
was determined in CV1 cells by transfect-
ing 5 g of reporter vectors without or
with 1 g of pSG5 empty vector or pSG5-
expressed putative coactivators ARA55
(55), HA-ARA54 (H54), ARA54 (54),
ARA70 (70), and TIF2 (TIF). Similar tran-
scriptional inhibition was observed with
0.7 g of pSG5 empty vector DNA rather
than 1 g, where 0.7 g was the molar
DNA equivalent used for the coactivators.
Panel C, transcriptional activity of AR
and AR mutants AR507–919 (DNA and
ligand binding domains), AR142–
337FXXAA (deletion of AF1 transactiva-
tion domain and mutation of the
23FXXLF27 motif), and AR142–337 (de-
letion of the AF1 NH2-terminal transacti-
vation domain). AR and AR mutant ex-
pression vector DNAs (100 ng/6-cm dish)
were transfected in the absence and pres-
ence of 1 g of pSG5 empty vector DNA
(pS5 or p) or pSG5-expressed TIF2 (TIF
or T), ARA54 (54), ARA55 (55), and
ARA70 (70). Cells were incubated for 48 h
in the absence and presence of 0.1 nM
DHT except for AR507–919, which was 10
nM DHT. In panels A–C, data shown are
representative of at least three independ-
ent experiments with fold induction
shown above the bars relative to activity
determined in the absence of DHT.
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pSG5 empty vector may be a valid control for ARA55, but AR
alone without the addition of empty vector DNA appears to be
the appropriate control for ARA54, ARA70, and TIF2 expres-
sion vectors. The results raise the possibility that the effects of
some AR coregulators on AR-mediated transcription have been
increased artificially by relating the androgen-induced activity
to the empty vector control.
Effects of Coactivators on AF2 Activity—We determined the
influence of the AR coregulators on AR AF2 activity using
several AR deletion mutants. Overexpression of TIF2 strongly
stimulates the AF2 activity of AR507–919, an AR DNA and
ligand binding domain fragment (Fig. 7C). In striking contrast,
ARA70,ARA54,andARA55each failed to increase theandrogen-
dependent AF2 activity of AR507–919 (Fig. 7C) despite the
presence of the FXXLF binding sequences in these AR coregu-
lators. TIF2 was the only coactivator tested which increased
the transcriptional activity of AR507–919 and AR142–337-
FXXAA. The latter AR mutant lacks the NH2-terminal AF1
residues 142–337 and has the NH2-terminal FXXLF motif mu-
tated to FXXAA (L26A/F27A) (Fig. 7C). Mutation of the FXXLF
motif allows access to the AF2 region, which is otherwise occu-
pied in the androgen-induced N/C interaction (19). None of the
coregulators, including TIF2, competed for the N/C interaction
to increase transactivation by AR142–337 (Fig. 7C). Thus in
contrast to classical coactivator activity, the reported AR coac-
tivators ARA54, ARA55, and ARA70 do not stimulate AR AF2
activity even though they are recruited to the AR ligand bind-
ing domain through their FXXLF motifs.
DISCUSSION
This report identifies FXXLF motifs in three previously re-
ported AR coactivators, which provides a molecular explana-
tion for their cloning in yeast two-hybrid screens using the AR
ligand binding domain as probe. FXXLF motifs in ARA54,
ARA55, and ARA70 interact to different degrees with the AF2
binding surface of the AR ligand binding domain. Interaction of
ARA55 was detected in GST affinity assays but only weakly in
mammalian two-hybrid assays. Protein interaction and ligand
dissociation rate studies indicated that the ARA54 FXXLF
motif binds the AR ligand binding domain to an extent some-
what weaker than the FXXLF motif in the AR NH2-terminal
region. Interaction of the ARA70 FXXLF motif was intermedi-
ate between ARA55 and ARA54. The studies revealed only
modest increases in AR transcriptional activity by the AR
coregulators, with no transcriptional activity detected through
their interaction with a ligand binding domain fragment
AR507–919. This contrasted the increase in transcriptional
activity induced by TIF2, a p160 coactivator with weaker in-
teracting LXXLL motifs. The results indicate that the AR co-
regulators ARA55, ARA54, and ARA70 likely function through
mechanisms that differ from those of the p160 coactivators.
Biochemical (3–6, 42) and x-ray crystallographic (43–45)
evidence established the recruitment of p160 coactivators by
steroid receptors as critical for transcription initiation. For
most steroid receptors, agonist-induced interactions occur be-
tween the AF2 hydrophobic surface in the ligand binding do-
main and the LXXLL motifs of p160 coactivators such as SRC1
and TIF2. However, the AR AF2 region in the ligand binding
domain preferentially binds FXXLF sequences, most notably
the 23FQNLF27 sequence in the AR NH2 terminus which me-
diates the androgen-induced N/C interaction (7, 15, 18, 20).
One of the functional consequences of the N/C interaction is to
inhibit the interaction of the LXXLL motif regions of the p160
coactivators with the same AF2 region in the AR ligand binding
domain (19). The FXXLF motif sequences in this group of
previously reported AR coregulators are located in regions that
were originally cloned in yeast two-hybrid screens using the AR
ligand binding domain as a probe (31–35). GST adsorption and
peptide mammalian two-hybrid assays indicate that the
FXXLF sequences interact with the AR ligand binding domain
in an agonist-dependent manner.
Data in this report show that FXXLF motifs interact selec-
tively with the AR ligand binding domain. This is based on
observations that none of the FXXLF peptide sequences in the
putative AR coactivators or in the AR NH2-terminal region
interact with ER, glucocorticoid, and progesterone receptors.
In contrast, the LXXLL sequences of the p160 coactivator TIF2
interact strongly with ER and the glucocorticoid and proges-
terone receptors, but only weakly with AR. AR selectivity for
the FXXLF motif sequences is supported by a recent report in
which only one LXXLL motif sequence (D11) interacted with
the AR in a phage display screen of an LXXLL consensus
peptide library using the ER ligand binding domain (29). The
FXXLF motif was also favored by the AR ligand binding do-
main when the D11-LXXLL sequence was mutated to FXXLF.
Chapman et al. (36) mutated peptide D11 LMQLL to FMQLF,
increasing by almost 4-fold its interaction with the AR ligand
binding domain and decreasing its interaction with the glu-
cocorticoid receptor. Similarly, when the carboxyl-terminal
LQQLL of SRC1 was changed to FQQLF, interaction with the
AR ligand binding domain increased from 2- to 378-fold,
whereas interaction with GR decreased from 450- to 75-fold
(36). Together the results provide strong evidence that the
FXXLF motif interacts preferentially with the AR ligand bind-
ing domain.
Many proteins have sequences that conform to the FXXLF
motif. The results of the present report indicate that the se-
quence determinants for interaction with the AR ligand bind-
ing domain lie within and flanking the FXXLF motif. For
example, FXXLF sequences present in two members of the
basal transcriptional machinery, TAFII250 (234FLRLF252) and
TFIIE (422FEDLF439), interacted only weakly with a 4–6-fold
increase in luciferase activity in two-hybrid peptide assays
with the AR (data not shown). Similarly no interaction was
observed between AR and the FXXLF motif peptides derived
from the general transcription coactivators CBP (23FGSLF41)
and p300 (26FGSLF44) or from the reported AR coactivator
FHL2 (25FETLF43). Clearly the FXXLF motif alone is not suf-
ficient to predict interaction with the AR ligand binding
domain.
Interacting FXXLF motifs likely form amphipathic -helical
structures as reported for the LXXLL motifs of p160 coactiva-
tors (3). This is supported by the failure of the CBP and p300
FXXLF motifs to interact with AR even though they are posi-
tioned near the coactivator NH2 terminus. The FXXLF motif
sequence present in CBP and p300 (FGSLF) contains the -he-
lix-disrupting amino acid glycine. Interaction of the FXXLF
sequence of the putative AR coactivator FHL2/DRAL, posi-
tioned near its NH2 terminus, was also not detected even
though a previous report indicated that FHL2/DRAL increases
AR activity in a N/C interaction-dependent manner (46). Thus
sequences within and flanking the FXXLF motif contribute to
the specificity of interaction with the AR ligand binding do-
main, where the precise sequence requirements remain to be
established. Other coactivators reported to interact with the
AR ligand binding domain lack the FXXLF motif. These include
Zac-1 (47), hsp40/dnaJ (48), and HBO1 (49), suggesting a dif-
ferent mechanism of interaction. An LXXLL motif sequence is
present in Zac-1 but not in hsp40/dnaJ or HBO1. Putative AR
coactivators reported to interact with the AR NH2-terminal or
DNA binding domains that also lack FXXLF motif sequences
include ARA24 (50), ARA160 (51), SNURF (52), ANPK (53),
Ubc9 (54), ARIP3/PIASx (55), Rb (56), and PIAS1 (57).
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The presence of FXXLF interacting motifs in the reported AR
coactivators ARA54, ARA55, and ARA70 raises the question of
whether these sequences function in vivo in their reported roles
as coactivators. We showed previously that interaction of the
AR NH2-terminal FXXLF motif with the AF2 region of the
ligand binding domain in the androgen-induced N/C interac-
tion suppresses AR interaction with p160 coactivators (19). The
weak interacting LXXLL motifs of p160 coactivators appar-
ently did not compete for the AF2 binding surface of the AR
ligand binding domain unless the coactivator was overex-
pressed. In contrast, the relative binding activities of the
FXXLF sequences from ARA54 and ARA70 in two-hybrid pep-
tide interaction assays suggest higher affinity interactions that
might be sufficient to compete with the AR NH2-terminal
FXXLF sequence in the presence of the androgen-induced N/C
interaction. Ligand dissociation kinetic studies of the coactiva-
tor-AR chimeras support the interaction of the ARA54 FXXLF
motif sequence but not that of ARA70. However, none of the
coactivators, including ARA54, ARA55, and ARA70, contained
strong transactivation domains like that of TIF2 as evidenced
by their failure to induce transactivation of the AR DNA and
ligand binding domain fragment.
The lack of strong transactivation by ARA54, ARA55, and
ARA70 raises the possibility that these coregulators function
through other mechanisms not directly related to AR transcrip-
tional activity. ARA54 was recently shown to be a RING finger
protein with ubiquitin ligase activity, although coexpression of
ARA54 did not influence AR degradation (58). Because RING
finger proteins transfer ubiquitin to themselves and other pro-
teins (59), it remains to be established whether this activity of
ARA54 contributes to AR function. ARA55/Hic-5 was cloned
from a human prostate cDNA library by two-hybrid screening
with the LNCaP mutant AR (AR-T877A) (33) and from a mouse
embryo library using mouse glucocorticoid receptor amino ac-
ids 513–562 as probe (34). ARA55 contains three LIM motifs
each consisting of a double zinc finger. Mouse ARA55/Hic-5
localized in focal cell-cell adhesions and nuclear matrix (34)
where it may transmit signals from cell attachment sites to
regulate transcription factors such as steroid receptors.
ARA55/Hic-5 was also cloned as an hsp27-binding protein (60),
consistent with the proposed function of LIM domain proteins
as protein interaction molecules. We reported earlier that
ARA70 interacts with the AR ligand binding domain and NH2-
terminal region (32) where the latter was independent of the
FXXLF motif. The mechanism of action of ARA70 remains to be
established.
Competition for protein-protein interaction sites is a poten-
tial mechanism whereby the AF2 region regulates AR activity
because the AF2 site is occupied by the N/C interaction in the
presence of androgen. Competition for protein interaction sites
in a domain swapping model has been proposed in the activa-
tion of HcK, a nonreceptor tyrosine kinase of the Src family (61,
62). Unlike the AR, which undergoes an androgen-dependent
interdomain N/C interaction in its active state, Hck kinase is
maintained in an inactive state by intramolecular interactions
between an NH2-terminal SH3 domain and a linker region, and
between an SH2 domain and a carboxyl-terminal phosphoty-
rosine (63). Competing proteins with similar interacting motifs
of the Hck kinase are human immunodeficiency virus Nef, a
high affinity ligand for Hck which has an SH3 domain, and
platelet-derived growth factor receptor, which has a phospho-
tyrosine. Each competes for the interdomain interactions of
Hck to activate the kinase (62, 64). The AR-associated proteins
in this study may be part of a larger group of proteins that
contain FXXLF motifs with sufficiently high affinity to compete
and interact with AF2 by interdomain competition.
Tissue-specific protein expression or altered cell homeostasis
may influence the availability of the AR AF2 region to tran-
scriptional activation. A majority of recurrent prostate cancer
specimens express levels of SRC1 and TIF2 significantly
greater than the levels detected in benign hyperplastic prostate
tissue and androgen-dependent prostate cancer (26). This
raised the possibility that AR is inappropriately activated
through AF2 by overexpressed p160 coactivators in the pres-
ence of low circulating androgen in the androgen-deprived
prostate cancer patient. In the presence of suppressed testicu-
lar androgen, interaction with p160 coactivators remains ligand-
dependent, but AF2 is more accessible to activation by overex-
pressed p160 coactivators because adrenal androgens are less
effective in inducing the N/C interaction (19). Specific AR
amino acid mutations that occur infrequently in prostate can-
cer may also contribute to the reactivity of the AR AF2 surface.
The AR N/C interaction site overlaps but is not identical to the
LXXLL binding site. Lysine 720 is required for interaction with
p160 coactivator LXXLL motif binding (7) and for the FXXLF
binding motif of ARA54, but not for the N/C interaction. A
somatic mutation of lysine 720 to glutamic acid occurred in a
bone metastases of hormone refractory prostate cancer (65),
which might influence the interaction specificity of the AF2
region. The AR-K720E mutant was reported to retain a normal
transcriptional response to androgen (65) typical of several
prostate cancer AR mutants (66) but could potentially present
an altered interacting surface for additional coactivator
binding.
A potentially important observation of the present study is
the apparent artificial inhibition of transactivation resulting
from cotransfection of empty expression vector DNA. The ad-
dition of balancing DNA is pervasive in the steroid receptor
field to account for transfected DNA of the putative coactivator
under study. Although there is no clear molecular explanation
for the apparent transcriptional inhibition, it is important be-
cause it renders apparent stimulatory activity to a cotrans-
fected protein which might otherwise not be observed. Inhibi-
tion by transfection of expression vector DNA that lacks
protein coding sequence could cause squelching of transcription
factor activity or inhibit receptor expression levels as suggested
recently (40).
The results indicate that the FXXLF motif is a common
mediator of androgen-dependent interactions selective for the
AR ligand binding domain. The FXXLF motif was originally
reported in the AR NH2-terminal domain to mediate the an-
drogen-dependent N/C interaction. Interdomain competition
may occur in a temporal sequence of FXXLF motif binding of
other proteins. The selectivity of FXXLF motif binding to the
AR indicates a role for flanking sequence in establishing spec-
ificity. The AR-interacting proteins studied in this report had
modest effects on AR transcriptional activation, suggesting
that they function through other mechanisms in regulating AR
function.
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